Brainstorm Cell Therapeutics Inc.
BCLIOTCHealthcare● Active
$0.80
+$0.05(+6.87%)
Market Cap$8827820
P/E Ratio—
52W High$1.33
52W Low$0.46
Brainstorm Cell Therapeutics Inc. (BCLI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BCLI · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.19
Est. -$0.28 · +32.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
BCLI reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 17, 2026 | -$0.29 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.28 | -$0.19 | +32.1% | — | — | — |
| ▲ Q1 FY2026 | Mar 31, 2026 | -$0.36 | -$0.20 | +44.4% | — | — | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$0.35 | -$0.91 | -160.0% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.41 | -$0.34 | +17.1% | — | — | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$0.97 | -$0.45 | +53.6% | — | — | — |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.49 | -$0.51 | -4.1% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.45 | -$1.80 | -300.0% | — | — | — |
Q3 FY2026
Aug 17, 2026
EPS Actual
—
EPS Est.
-$0.29
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.19
EPS Est.
-$0.28
EPS Surpr.
+32.1%
Revenue
—
Q1 FY2026
Mar 31, 2026Beat
EPS Actual
-$0.20
EPS Est.
-$0.36
EPS Surpr.
+44.4%
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$0.91
EPS Est.
-$0.35
EPS Surpr.
-160.0%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.34
EPS Est.
-$0.41
EPS Surpr.
+17.1%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.45
EPS Est.
-$0.97
EPS Surpr.
+53.6%
Revenue
—
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$0.51
EPS Est.
-$0.49
EPS Surpr.
-4.1%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$1.80
EPS Est.
-$0.45
EPS Surpr.
-300.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Q3 FY2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q2 FY2026 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q1 FY2026 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q4 FY2025 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q3 FY2025 | $-0.37 | $-0.37 | $-0.37 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +32.1% | $0.69 | $0.69 | -0.57% |
| ▲ Q1 FY2026 | Mar 31, 2026 | +44.4% | $0.87 | $0.95 | +9.17% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -160.0% | $0.63 | $0.61 | -3.17% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +17.1% | $0.66 | $0.60 | -9.09% |
| ▲ Q2 FY2025 | May 15, 2025 | +53.6% | $1.14 | $1.16 | +1.75% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -4.1% | $1.19 | $1.26 | +5.88% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -300.0% | $1.17 | $1.13 | -3.42% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +0.0% | $4.79 | $4.58 | -4.38% |
Q2 FY2026-0.57%
Report Date
May 15, 2026
EPS Beat/Miss
+32.1%
Price Before
$0.69
Price After
$0.69
Q1 FY2026+9.17%
Report Date
Mar 31, 2026
EPS Beat/Miss
+44.4%
Price Before
$0.87
Price After
$0.95
Q4 FY2025-3.17%
Report Date
Nov 14, 2025
EPS Beat/Miss
-160.0%
Price Before
$0.63
Price After
$0.61
Q3 FY2025-9.09%
Report Date
Aug 14, 2025
EPS Beat/Miss
+17.1%
Price Before
$0.66
Price After
$0.60
Q2 FY2025+1.75%
Report Date
May 15, 2025
EPS Beat/Miss
+53.6%
Price Before
$1.14
Price After
$1.16
Q1 FY2025+5.88%
Report Date
Mar 31, 2025
EPS Beat/Miss
-4.1%
Price Before
$1.19
Price After
$1.26
Q4 FY2024-3.42%
Report Date
Nov 14, 2024
EPS Beat/Miss
-300.0%
Price Before
$1.17
Price After
$1.13
Q3 FY2024-4.38%
Report Date
Aug 14, 2024
EPS Beat/Miss
+0.0%
Price Before
$4.79
Price After
$4.58
Avg Beat Reaction-0.62%
Avg Miss Reaction-0.24%
Beat Rate5 / 8 quarters
Largest Move+9.17% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BCLI ends December
Brainstorm Cell Therapeutics Inc. (BCLI) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.19 — beating the analyst consensus of $-0.28 by +32.1%. BCLI has beaten EPS estimates for 2 consecutive quarters. The next BCLI earnings date is expected around September 1, 2026.
Each quarter, investors track BCLI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BCLI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BCLI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BCLI earnings · 5 questionsBrainstorm Cell Therapeutics Inc.'s next earnings report is expected around September 1, 2026. BCLI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BCLI historically reports after market close (AMC).
BCLI earnings datewhen is BCLI earningsBCLI next earnings datewhen does BCLI report earningsBCLI earnings calendar
▸ Source: FMP · Brainstorm Cell Therapeutics Inc. SEC filings · US GAAP · Brainstorm Cell Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026